On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses induced by INOVIO’s DNA vaccine candidate for COVID-19, INO-4800, against variants of concern.

The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain.